347 related articles for article (PubMed ID: 23538467)
1. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM
Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
Mustafa RE; DeStefano LM; Bahng J; Yoon-Flannery K; Fisher CS; Zhang PJ; Tchou J; Czerniecki BJ; De La Cruz LM
Ann Surg Oncol; 2017 Oct; 24(10):2999-3003. PubMed ID: 28766212
[TBL] [Abstract][Full Text] [Related]
3. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.
Bryan BB; Schnitt SJ; Collins LC
Mod Pathol; 2006 May; 19(5):617-21. PubMed ID: 16528377
[TBL] [Abstract][Full Text] [Related]
4. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
5. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
6. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
[TBL] [Abstract][Full Text] [Related]
7. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
8. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
[TBL] [Abstract][Full Text] [Related]
9. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
[TBL] [Abstract][Full Text] [Related]
10. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
11. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
12. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.
Schandiz H; Park D; Kaiser YL; Lyngra M; Talleraas IS; Geisler J; Sauer T
Breast Cancer Res Treat; 2023 Sep; 201(2):329-338. PubMed ID: 37453021
[TBL] [Abstract][Full Text] [Related]
13. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
14. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
16. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
17. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.
Harada S; Mick R; Roses RE; Graves H; Niu H; Sharma A; Schueller JE; Nisenbaum H; Czerniecki BJ; Zhang PJ
J Surg Oncol; 2011 Oct; 104(5):458-65. PubMed ID: 21557226
[TBL] [Abstract][Full Text] [Related]
18. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
[TBL] [Abstract][Full Text] [Related]
19. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
[TBL] [Abstract][Full Text] [Related]
20. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
